Léonello CusanM.D.

Goldstein I, Bélanger A, Cusan L, Archer D, Nappi RE, Portman D, Gudeman J

In Memoriam: Fernand Labrie, June 28, 1937 – January 16, 2019

Sex Med Rev, 7 (2), 2019.

| Liens:

Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Cote I, Martel C, Vaillancourt M, Balser J, Moyneur E,

Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study

Horm Mol Biol Clin Investig, 25 (3), 2016.

Résumé | Liens:

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E,

Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause

Menopause, 23 (3), 2016.

Résumé | Liens:

Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Cote I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur E,

Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy

J Sex Med, 12 (12), 2015.

Résumé | Liens:

Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Cote I, Lavoie L, Martel C, Balser J,

Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)

Menopause, 22 (9), 2015.

Résumé | Liens:

Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dube R,

Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women

Menopause, 22 (12), 2015.

Résumé | Liens:

Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Cote I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur E,

Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study

Maturitas, 81 (1), 2015.

Résumé | Liens:

Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote I, Labrie C, Lavoie L, Gilbert L, Martel C, Balser J

Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women

J Sex Med, 11 (7), 2014.

Résumé | Liens:

Labrie F, Martel C, Berube R, Cote I, Labrie C, Cusan L, Gomez JL

Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens

J Steroid Biochem Mol Biol, 138 , 2013.

Résumé | Liens:

Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J

Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia

Climacteric, 14 (2), 2011.

Résumé | Liens: